Studies: Spending on Accelerated Approval Drugs Is Growing Fast

  • The FDA’s accelerated approval pathway for experimental therapies has been criticized by practitioners and health insurers in recent months following the controversial approval of Alzheimer’s drug Aduhelm (aducanumab). Aduhelm is just the latest of many experimental therapies that has been approved with limited clinical evidence of efficacy — and payers and independent researchers say the FDA should revamp the process to contain costs. Read more
  • Peter Johnson

    Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

The Latest
Meet Our Reporters

Meet Our Reporters

×
×